Orthomyxoviridae (e.g., Influenza Virus, Fowl Plague Virus, Etc.) Patents (Class 424/209.1)
  • Patent number: 10849978
    Abstract: The present invention is intended to provide a nose drop having high absorption of peptide hormone oxytocin or an acid addition salt thereof, or a derivative thereof through nasal mucosa and little safety concern. The present invention is a pharmaceutical composition for administration to nasal mucosa containing oxytocin or an acid addition salt thereof, or a derivative thereof and a carboxyvinyl polymer, characterized by having an osmotic pressure ratio less than 1.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 1, 2020
    Assignee: Teijin Pharma Limited
    Inventors: Susumu Maruo, Atsuhiro Nagano, Yuko Nonaka, Ryo Furukawa
  • Patent number: 10842868
    Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: November 24, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Barbara Baudner, Derek O'Hagan, Manmohan Singh, Simone Bufali
  • Patent number: 10835601
    Abstract: Disclosed herein is a vaccine comprising an antigen and a protein, peptide, or carbohydrate of Chlamydia spp., or a fragment thereof, wherein the antigen is not derived from a Chlamydia spp. Also disclosed are methods of treating or preventing diseases comprising administering to a subject a vaccine, wherein the vaccine comprises an antigen and a protein, peptide, or carbohydrate of Chlamydia spp., or a fragment thereof, wherein the antigen is not derived from a Chlamydia spp.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: November 17, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas Cherpes, Nirk E. Quispe Calla, Rodolfo Daniel Vicetti Miguel
  • Patent number: 10813991
    Abstract: The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a Marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting Marek's disease in combination with at least a second disease in poultry.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 27, 2020
    Assignee: The Texas A&M University System
    Inventors: Sanjay M. Reddy, Blanca M. Lupiani
  • Patent number: 10806698
    Abstract: A composition for oral administration of a bioactive agent to aquatic or terrestrial species includes particles each of which includes a bioactive agent dispersed in oil droplets, the oil droplets being dispersed in a matrix including an enteric coating polymer, wherein the particles each further include a mucoadhesive polymer. Methods of making and using the composition are also provided.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 20, 2020
    Assignee: Intervet Inc.
    Inventors: Moti Harel, Swetha Kambalapally
  • Patent number: 10772954
    Abstract: The present invention relates to vaccines comprising an effective amount of at least one antigen in a water-in-oil-in-water (WOW) emulsion and an additional adjuvant, and to the methods of preparation and uses thereof.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: September 15, 2020
    Assignee: Biomune Company
    Inventors: Roger H. Ruehling, Brianna Ford
  • Patent number: 10765735
    Abstract: This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: September 8, 2020
    Assignee: EpitoGenesis, Inc.
    Inventors: Michael Vajdy, Shohre Golestani
  • Patent number: 10751361
    Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: August 25, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Albert Abraham, Daniel Keil, Jason Nickell, Christian Weiss
  • Patent number: 10695326
    Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: June 30, 2020
    Assignee: Drexel University
    Inventors: Christian Sell, Timothy Nacarelli, Ashley Azar
  • Patent number: 10695418
    Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 30, 2020
    Assignee: TECHNOVAX, INC.
    Inventors: Jose M. Galarza, George R. Martin
  • Patent number: 10570367
    Abstract: Provided herein are seed train processes and methods of producing a recombinant protein that include the use of these seed train processes.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: February 25, 2020
    Assignee: Genzyme Corporation
    Inventors: Michael Bruninghaus, Konstantin Konstantinov, Benjamin Wright, Weichang Zhou
  • Patent number: 10537628
    Abstract: The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a Marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting Marek's disease in combination with at least a second disease in poultry.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 21, 2020
    Assignee: The Texas A&M University System
    Inventors: Sanjay M. Reddy, Blanca M. Lupiani
  • Patent number: 10525122
    Abstract: The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: January 7, 2020
    Assignee: KM Biologics Co., Ltd.
    Inventors: Kazuhiko Kimachi, Motoharu Abe, Kazuyuki Ikeda, Hiroto Onuma, Yukari Tsurudome, Daisuke Ikeno, Kiyoto Nishiyama, Tatsufumi Onchi, Yusuke Ooyama, Issay Asano, Ryoichi Kitano
  • Patent number: 10502709
    Abstract: The electrophoresis method includes the following steps: electrically injecting a sample into an electrophoresis flow path through one end thereof; subjecting the injected sample to electrophoresis to be separated by applying a voltage to both ends of the electrophoresis flow path; detecting the separated sample component at a detection position of the electrophoresis flow path; obtaining a peak area of the detected sample component; and correcting the obtained peak area on the basis of an injection rate of each sample component. Correction based on the injection rate includes, a correction based on a relative mobility of the sample component and at least one of: a correction based on the linear velocity at the time of sample injection for each sample component and a correction based on the current integral value at the time of sample injection.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 10, 2019
    Assignee: SHIMADZU CORPORATION
    Inventor: Akihiro Arai
  • Patent number: 10493146
    Abstract: The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: December 3, 2019
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Junwei Li
  • Patent number: 10487312
    Abstract: Formulations and methods are disclosed for the harvesting and subsequent passaging of human pluripotent stem cells without the use of enzymes and/or scraping to dislodge cells from cell culture vessels. The formulations and methods permit the harvesting of cells as large clusters from the surface of various cell culture vessels including multilayer cell culture vessels. Further, the formulations and methods provide high yields of harvested cells for subsequent passaging and high post-harvest cell viability. Pluripotent stem cells passaged with the formulations according to the methods remain undifferentiated and express typical stem cell markers, while, at the same time, they retain the differentiation capability and are able to differentiate into the cells in all three germ layers and generate teratomas, even after numerous rounds of harvesting and passaging. These hPSCs also maintain normal karyotype after passaged with the formulations for extended period of time.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: November 26, 2019
    Assignee: LONZA WALKERSVILLE INC.
    Inventors: Ying Nie, Jonathan Allen Rowley, Thomas Fellner, Patrick Walsh
  • Patent number: 10428316
    Abstract: The present invention relates to immortalized chicken embryo fibroblasts, to cell cultures comprising such immortalized cells, to vaccines comprising such cells, to methods for the propagation of avian viruses on such cells, and to methods for the preparation of such cells and such vaccines.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 1, 2019
    Assignee: Intervet Inc.
    Inventor: Jaap Kool
  • Patent number: 10426827
    Abstract: Provided are methods of selecting domains of the dengue hemorrhagic fever virus E protein for generating a neutralizing antibody immune response to the dengue hemorrhagic fever virus. The method comprises priming an individual by administering a mixture of expression vectors encoding fusion proteins or the fusion proteins themselves which comprises the DHFV E antigen fragment linked to the extracellular domain of the CD40 ligand. The expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing the DHFV E antigen fragment linked to the CD40 ligand. The methods may be used to immunize an individual against all four strains of dengue hemorrhagic fever virus.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: October 1, 2019
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10392604
    Abstract: The present invention relates to the field of medicine and virology. An attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof are provided, which can be used for the prevention and/or treatment of an infectious disease. In addition, the present invention relates to an attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof, which can be used for the treatment of oncological diseases.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 27, 2019
    Assignee: PHARMENTERPRISES BIOTECH Limited Liability Company
    Inventors: Andrei Yurievich Egorov, Boris Ferko, Artem Alexandrovich Krokhin, Yulia Romanovna Romanova
  • Patent number: 10369213
    Abstract: Methods for improving the drying yield and stability of RSV vaccines comprising a highly thermolabile enveloped live virus and/or one or more RSV protein subunits, are described. Methods for rapid drying of RSV formulations containing between 17.5% and 60% w/w of a non-polymeric sugar and using either conduction or radiation dominant drying mechanisms, are disclosed. The disclosed methods provide for; 1) a dried RSV formulation with improved stability profile; 2) faster drying; and 3) integration of dried RSV into a primary device (such as dual chamber cartridges, foil-pouch devices etc.), pre- as well as post-drying.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Lynne A. Isopi
  • Patent number: 10344261
    Abstract: The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: July 9, 2019
    Assignee: ASCEND BIOPHARMACEUTICALS LTD
    Inventors: Geoffrey Alan Pietersz, Clement Leong
  • Patent number: 10273462
    Abstract: The present invention provides viral vector compositions of high titer and purity, as well as methods for production of said compositions. The methods of the invention incorporate multiple features, such as production of viral vector particles in serum free media and multiple harvesting steps following transduction of the producer cell which provides for enhanced production of said viral vectors. The viral vector compositions of the invention, by virtue of their high titer and purity, minimize the deleterious phenotypic changes that typically occur following transduction of target cells, such as loss of a sub-populations of transduced cells, and effects on proliferation, differentiation, reprogramming or functionality of transduced cells.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 30, 2019
    Assignee: Vectalys SAS
    Inventors: Pascale Bouillé, Hélène Vergnault, Régis Gayon, Yohann Moal
  • Patent number: 10232031
    Abstract: New influenza donor strains for the production of reassortant influenza B viruses are provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 19, 2019
    Assignees: Seqirus UK Limited, Synthetic Genomics, Inc.
    Inventors: Philip Dormitzer, Peter Mason, Pirada Suphaphiphat, Raul Gomila
  • Patent number: 10080778
    Abstract: Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: September 25, 2018
    Assignee: Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 9981034
    Abstract: Disclosed herein are compositions and methods useful for immunizing a subject against disease caused by influenza A. Disclosed methods comprise administering to the subject an immunoprotective dose of an immunogenic composition. In certain aspects, the immunogenic composition is a vaccine comprised of a recombinant chimeric hemagglutinin polypeptide. In certain aspects, the subject is a mammal. In further aspects, the mammal is a pig. In still further aspects, the mammal is a human.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 29, 2018
    Assignee: South Dakota Board of Regents
    Inventors: Victor Huber, Ying Fang
  • Patent number: 9975925
    Abstract: Novel influenza antigens, novel immunogenic or vaccine compositions, as well as uses of and methods for producing said antigens and compositions, are described.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: May 22, 2018
    Assignees: GLAXOSMITHKLINE BIOLOGICALS S.A., THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. HEALTH & HUMAN SERVICES
    Inventors: James Stevens, Ruben Donis, David Shore, Hongquan Wan, Ventzislav Bojidarov Vassilev
  • Patent number: 9969984
    Abstract: Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a pH value of the preparation in the range of 6.0-8.0; and c) a carbohydrate.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: May 15, 2018
    Assignee: BEIJING SOLOBIO GENETECHNOLOGY COMPANY LTD.
    Inventors: Jundie Fan, Lixin Jiang, Zhiwen Zhou
  • Patent number: 9943588
    Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 17, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Emmanuel Jules Hanon, Jean Stephenne
  • Patent number: 9901634
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 27, 2018
    Assignee: NOVAVAX AB
    Inventors: Bror Morein, Karin Lovgren Bengtsson
  • Patent number: 9855328
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 2, 2018
    Assignees: AUBURN UNIVERSITY, ALTIMMUNE INC.
    Inventors: De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro
  • Patent number: 9821064
    Abstract: Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R1, R2, and R3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH3)3NO. The formulation is useful for vaccine stabilization.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: November 21, 2017
    Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: Tianxiao Sun, Philip M. Levesque, Alicja T. Brown, Cynthia K. Lee
  • Patent number: 9775911
    Abstract: The present invention provides among other things a composition of a polymeric reagent and an antioxidant, such as butylated hydroxyl toluene.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 3, 2017
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
  • Patent number: 9730999
    Abstract: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: August 15, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Emmanuel Jules Hanon, Jean Stephenne
  • Patent number: 9708585
    Abstract: New influenza donor strains for the production of reassortant influenza A viruses are provided.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: July 18, 2017
    Assignee: Seqirus UK Limited
    Inventors: Peter Mason, Philip Ralph Dormitzer, Heidi Trusheim, Pirada Suphaphiphat
  • Patent number: 9657359
    Abstract: The invention relates to generic methods for the detection and quantification of mammalian reoviruses. These may uses a reverse transcription (RT-PCR) real time (q-PCR) assay which amplifies a conserved region within all MRV types. The assays allow the quantification of MRV RNA molecules, irrespective of the particular virus type (e.g. MRV-1, MRV-2). The methods are particularly applicable in the monitoring of vaccine production processes.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: May 23, 2017
    Assignee: Novartis AG
    Inventor: Bernhard Roth
  • Patent number: 9637522
    Abstract: Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: May 2, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yuan Lu, James R. Swartz
  • Patent number: 9623105
    Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 18, 2017
    Assignee: MERIAL, INC.
    Inventor: Benjamin M. Hause
  • Patent number: 9623104
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 18, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 9441207
    Abstract: Animal cells are described which can be infected by viruses and which are adapted to growth in suspension in medium free of animal-derived components, such as serum-free medium. Processes for the replication of viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the viruses or antigenic portions thereof obtainable by the process.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 13, 2016
    Assignee: Intervet Inc.
    Inventors: Monty R. Warthen, William F. Skotta
  • Patent number: 9410212
    Abstract: The invention relates to a method of detecting the presence of Salmonella in a sample using novel oligonucleotide sequences. Also presented is a kit for putting the method into practice and novel nucleic acid sequences for ompF. The ompF gene was found to be 100% inclusive for Salmonella species and 100% exclusive for non-Salmonella species for the strains tested thus making it an excellent marker for identification of both the species of Salmonella: S. enterica and S. bongori. Two hundred and eighteen isolates belonging to Salmonella enterica (subspecies I-VI) and Salmonella bongori were examined using novel primers designed to detect the ompF gene. The target was present in all the 218 Salmonella isolates including all the subspecies of Salm. enterica and Salm. bongori. The ompF gene was absent in 180 non-Salmonella strains tested.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: August 9, 2016
    Assignee: University of South Florida
    Inventors: Aparna Tatavarthy, Andrew C. Cannons, Loree C. Heller
  • Patent number: 9403878
    Abstract: Methods for producing virus particles with simplified glycosylation on structural or surface proteins, such as mono-glycosylated forms of influenza A virus, NIBRG-14 (H5N1). When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations. Such methods may include the use of glycosylation inhibitors for production of viruses with simplified glycosylation profiles.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: August 2, 2016
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Che Ma, Yung-Chieh Tseng
  • Patent number: 9327137
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: May 3, 2016
    Assignee: MERIAL, INC.
    Inventors: Jean-Christophe Audonnet, Jules Minke
  • Patent number: 9278126
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: March 8, 2016
    Assignee: Seqirus UK Limited
    Inventors: Mario Contorni, Derek O'hagan, Nicola Groth
  • Patent number: 9216211
    Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: December 22, 2015
    Assignee: MERIAL, INC.
    Inventor: Benjamin M Hause
  • Patent number: 9150620
    Abstract: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: October 6, 2015
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Shih-Chang Lin
  • Patent number: 9138471
    Abstract: The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: September 22, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Nathalie Garcon, Moncef Mohamed Slaoui, Christian Van Hoecke
  • Patent number: 9089537
    Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: July 28, 2015
    Assignees: The Trustees of the University of Pennslyvania, Juvaris Biotherapeutics, Inc.
    Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 9072701
    Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: July 7, 2015
    Assignees: St. Jude Children's Research Hospital, Zoetis Services LLC
    Inventors: Erich Hoffmann, Scott L. Krauss, Mahesh Kumar, Richard J. Webby, Robert G. Webster
  • Patent number: 9040296
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: May 26, 2015
    Assignee: Valneva
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Publication number: 20150140036
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Applicant: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
    Inventors: Joan Mannick, David Glass, Leon Murphy